Surgical septal myectomy for relief of dynamic obstruction in Anderson-Fabry Disease

Zahara Meghji, Anita Nguyen, William R. Miranda, Jeffrey B. Geske, Hartzell V Schaff, Dawn S. Peck, Darrell B. Newman

Research output: Contribution to journalArticle

Abstract

Patients with Anderson-Fabry Disease (AFD) and severe left ventricular hypertrophy complicated by left ventricular outflow tract (LVOT) obstruction may benefit from surgical septal myectomy (SSM). Mid- and late outcomes following surgery have not been established, and we sought to better characterize postoperative outcomes following septal myectomy. Between January 2011 and June 2017, 7 patients (6 females) with AFD underwent SSM. The median (range) age at the time of surgery was 53 (37–72) years; 4 patients had a positive family history of AFD and a preoperative diagnosis of AFD. Extracardiac features suggestive of AFD were present in 3 patients and all but 1 (female) had reduced α-galactosidase A activity. All patients had severe left ventricular hypertrophy and LVOT obstruction on transthoracic echocardiography. Preoperatively, all patients were severely symptomatic with New York Heart Association (NYHA) class III symptoms. There was no early mortality following surgery. The median in-hospital length of stay was 5 (4–7) days with 6 patients reporting NYHA class II or less symptoms at 3 month follow-up. Long-term outcomes were favorable with 4 patients reporting sustained NYHA class II or less symptoms, but 2 patients had recurrence of NYHA class III symptoms without evidence of recurrent LVOT obstruction. In conclusion, SSM appears to provide favorable short- and long-term relief of severe, symptomatic LVOT obstruction but may not alter progression of Fabry cardiomyopathy.

Original languageEnglish (US)
JournalInternational Journal of Cardiology
DOIs
StatePublished - Jan 1 2019

Fingerprint

Fabry Disease
Ventricular Outflow Obstruction
Left Ventricular Hypertrophy
Length of Stay
Galactosidases
Cardiomyopathies
Echocardiography
Recurrence

Keywords

  • Fabry
  • Hypertrophic cardiomyopathy
  • Myectomy
  • Obstruction

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Surgical septal myectomy for relief of dynamic obstruction in Anderson-Fabry Disease. / Meghji, Zahara; Nguyen, Anita; Miranda, William R.; Geske, Jeffrey B.; Schaff, Hartzell V; Peck, Dawn S.; Newman, Darrell B.

In: International Journal of Cardiology, 01.01.2019.

Research output: Contribution to journalArticle

Meghji, Zahara ; Nguyen, Anita ; Miranda, William R. ; Geske, Jeffrey B. ; Schaff, Hartzell V ; Peck, Dawn S. ; Newman, Darrell B. / Surgical septal myectomy for relief of dynamic obstruction in Anderson-Fabry Disease. In: International Journal of Cardiology. 2019.
@article{61ef723f06ee4b41bf7a594c3976f326,
title = "Surgical septal myectomy for relief of dynamic obstruction in Anderson-Fabry Disease",
abstract = "Patients with Anderson-Fabry Disease (AFD) and severe left ventricular hypertrophy complicated by left ventricular outflow tract (LVOT) obstruction may benefit from surgical septal myectomy (SSM). Mid- and late outcomes following surgery have not been established, and we sought to better characterize postoperative outcomes following septal myectomy. Between January 2011 and June 2017, 7 patients (6 females) with AFD underwent SSM. The median (range) age at the time of surgery was 53 (37–72) years; 4 patients had a positive family history of AFD and a preoperative diagnosis of AFD. Extracardiac features suggestive of AFD were present in 3 patients and all but 1 (female) had reduced α-galactosidase A activity. All patients had severe left ventricular hypertrophy and LVOT obstruction on transthoracic echocardiography. Preoperatively, all patients were severely symptomatic with New York Heart Association (NYHA) class III symptoms. There was no early mortality following surgery. The median in-hospital length of stay was 5 (4–7) days with 6 patients reporting NYHA class II or less symptoms at 3 month follow-up. Long-term outcomes were favorable with 4 patients reporting sustained NYHA class II or less symptoms, but 2 patients had recurrence of NYHA class III symptoms without evidence of recurrent LVOT obstruction. In conclusion, SSM appears to provide favorable short- and long-term relief of severe, symptomatic LVOT obstruction but may not alter progression of Fabry cardiomyopathy.",
keywords = "Fabry, Hypertrophic cardiomyopathy, Myectomy, Obstruction",
author = "Zahara Meghji and Anita Nguyen and Miranda, {William R.} and Geske, {Jeffrey B.} and Schaff, {Hartzell V} and Peck, {Dawn S.} and Newman, {Darrell B.}",
year = "2019",
month = "1",
day = "1",
doi = "10.1016/j.ijcard.2019.06.042",
language = "English (US)",
journal = "International Journal of Cardiology",
issn = "0167-5273",
publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - Surgical septal myectomy for relief of dynamic obstruction in Anderson-Fabry Disease

AU - Meghji, Zahara

AU - Nguyen, Anita

AU - Miranda, William R.

AU - Geske, Jeffrey B.

AU - Schaff, Hartzell V

AU - Peck, Dawn S.

AU - Newman, Darrell B.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Patients with Anderson-Fabry Disease (AFD) and severe left ventricular hypertrophy complicated by left ventricular outflow tract (LVOT) obstruction may benefit from surgical septal myectomy (SSM). Mid- and late outcomes following surgery have not been established, and we sought to better characterize postoperative outcomes following septal myectomy. Between January 2011 and June 2017, 7 patients (6 females) with AFD underwent SSM. The median (range) age at the time of surgery was 53 (37–72) years; 4 patients had a positive family history of AFD and a preoperative diagnosis of AFD. Extracardiac features suggestive of AFD were present in 3 patients and all but 1 (female) had reduced α-galactosidase A activity. All patients had severe left ventricular hypertrophy and LVOT obstruction on transthoracic echocardiography. Preoperatively, all patients were severely symptomatic with New York Heart Association (NYHA) class III symptoms. There was no early mortality following surgery. The median in-hospital length of stay was 5 (4–7) days with 6 patients reporting NYHA class II or less symptoms at 3 month follow-up. Long-term outcomes were favorable with 4 patients reporting sustained NYHA class II or less symptoms, but 2 patients had recurrence of NYHA class III symptoms without evidence of recurrent LVOT obstruction. In conclusion, SSM appears to provide favorable short- and long-term relief of severe, symptomatic LVOT obstruction but may not alter progression of Fabry cardiomyopathy.

AB - Patients with Anderson-Fabry Disease (AFD) and severe left ventricular hypertrophy complicated by left ventricular outflow tract (LVOT) obstruction may benefit from surgical septal myectomy (SSM). Mid- and late outcomes following surgery have not been established, and we sought to better characterize postoperative outcomes following septal myectomy. Between January 2011 and June 2017, 7 patients (6 females) with AFD underwent SSM. The median (range) age at the time of surgery was 53 (37–72) years; 4 patients had a positive family history of AFD and a preoperative diagnosis of AFD. Extracardiac features suggestive of AFD were present in 3 patients and all but 1 (female) had reduced α-galactosidase A activity. All patients had severe left ventricular hypertrophy and LVOT obstruction on transthoracic echocardiography. Preoperatively, all patients were severely symptomatic with New York Heart Association (NYHA) class III symptoms. There was no early mortality following surgery. The median in-hospital length of stay was 5 (4–7) days with 6 patients reporting NYHA class II or less symptoms at 3 month follow-up. Long-term outcomes were favorable with 4 patients reporting sustained NYHA class II or less symptoms, but 2 patients had recurrence of NYHA class III symptoms without evidence of recurrent LVOT obstruction. In conclusion, SSM appears to provide favorable short- and long-term relief of severe, symptomatic LVOT obstruction but may not alter progression of Fabry cardiomyopathy.

KW - Fabry

KW - Hypertrophic cardiomyopathy

KW - Myectomy

KW - Obstruction

UR - http://www.scopus.com/inward/record.url?scp=85067988596&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85067988596&partnerID=8YFLogxK

U2 - 10.1016/j.ijcard.2019.06.042

DO - 10.1016/j.ijcard.2019.06.042

M3 - Article

JO - International Journal of Cardiology

JF - International Journal of Cardiology

SN - 0167-5273

ER -